```
=> b reg
FILE 'REGISTRY' ENTERED AT 14:48:58 ON 17 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 AUG 2009  HIGHEST RN 1174375-84-8
DICTIONARY FILE UPDATES:  16 AUG 2009  HIGHEST RN 1174375-84-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l8
L5              STR
```




```
VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E7 C  E2 N  AT   1
ECOUNT  IS E4 C  E1 O  AT   3

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   9

STEREO ATTRIBUTES: NONE
L6          225 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC2NC3 AND
                OC4)/ES
L8           14 SEA FILE=REGISTRY SUB=L6 SSS FUL L5

100.0% PROCESSED     159 ITERATIONS                           14 ANSWERS
SEARCH TIME: 00.00.01



=> b zcap
FILE 'ZCAPLUS' ENTERED AT 14:49:04 ON 17 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 17 Aug 2009  VOL 151 ISS 8
```

FILE LAST UPDATED: 16 Aug 2009 (20090816/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> d bib abs hitstr l17 tot

L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:823712 ZCAPLUS

DN 143:229891

TI Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands, their preparation and pharmaceutical compositions

IN Peters, Dan; Olsen, Gunnar M.; Nielsen, Elsebet Ostergaard; Jorgensen, Tino Dyhring; Anring, Philip K.; Timmermann, Daniel B.

PA Neurosearch A/S, Den.

SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005075482	A1	20050818	2005WO-EP0050405	20050201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NG, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2005210039	A1	20050818	2005AU-000210039	20050201
CA-----2555311	A1	20050818	2005CA-002555311	20050201
EP-----1713810	A1	20061025	2005EP-000716606	20050201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN-----1922186	A	20070228	2005CN-080004139	20050201
CN---100432075	C	20081112		
BR--2005006881	A	20070626	2005BR-000006881	20050201
JP--2007520527	T	20070726	2006JP-000551845	20050201
US-20080227772	A1	20080918	2006US-000586749	20060721
MX--2006008749	A	20061030	2006MX-000008749	20060802
IN---200602846	A	20070706	2006IN-000002846	20060803
PRAI 2004DK-000000169	A	20040204		
2004US-00541754P	P	20040205		
2004DK-000000839	A	20040528		
2004US-00574946P	P	20040528		
2005WO-EP0050405	W	20050201		

OS CASREACT 143:229891; MARPAT 143:229891

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of diazabicyclic aryl derivs. I, including its enantiomers, N-oxides, prodrugs, and pharmaceutically acceptable salts, which are cholinergic ligands at the nicotinic acetylcholine receptors. In compds. I, n is 1-3; X and Y are independently selected from (un)substituted aromatic monocyclic/polycyclic carbocycles/heterocycles; Z is an (un)substituted monocyclic heterocycle, amino, (thio)carbonylamino, imidamido, ureido, thioureido, or guanidino; and L is a bond, CH2, CH2CH2, CH=CH, C.tplbond.C, O, S, SCH2, etc. The invention also relates to the preparation of I, pharmaceutical comps. containing I or a pharmaceutically acceptable salt of I, together with at least one pharmaceutically acceptable carrier or diluent, as well as to the use of the comps. for the treatment of diseases and disorders associated with nicotinic acetylcholine receptors. 3-Quinuclidinone hydrochloride was condensed with hydroxylamine and ring expansion followed by reduction with LiAlH4 resulted in the formation of 1,4-diazabicyclo[3.2.2]nonane (II). II was acylated with 5-(4-nitrophenyl)-2-furoyl chloride (preparation in situ from the corresponding acid is given) to give III. Palladium-catalyzed hydrogenation of III followed by addition to Et isocyanate gave diazabicyclic derivative IV. Compound IV expressed IC50 value of 0.56 nM in a study on the

L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 862851-89-6 ZCAPLUS

CN Benzamide, 3-amino-N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

inhibition of [3H]-α-bungarotoxin in rat brain, representing the α7-subtype of nicotinic receptors.

IT **753499-87-5P**, N-[4-[5-[(1,4-Diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]benzamide **862851-87-4P**, 4-Amino-N-[4-[5-[(1,4-diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]benzamide **862851-89-6P**, 3-Amino-N-[4-[5-[(1,4-diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]benzamide **862852-29-7P**, N-[3-[5-[(1,4-Diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]benzamide **862852-30-0P** **862852-33-3P**, N-[4-[5-[(1,4-Diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]-2-nitrobenzamide hydrochloride **862852-43-5P**, N-[4-[5-[(1,4-diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]-2-nitrobenzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diazabicyclic aryl derivs. as nicotinic acetylcholine receptor ligands)

RN 753499-87-5 ZCAPLUS

CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]- (CA INDEX NAME)



RN 862851-87-4 ZCAPLUS

CN Benzamide, 4-amino-N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]- (CA INDEX NAME)

L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-A

RN 862852-29-7 ZCAPLUS

CN Benzamide, N-[3-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]- (CA INDEX NAME)



RN 862852-30-0 ZCAPLUS

CN Benzamide, N-[3-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 862852-29-7

CMF C25 H25 N3 O3



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 862852-33-3 ZCAPLUS
CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-2-nitro-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● HCl

RN 862852-43-5 ZCAPLUS
CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-2-nitro- (CA INDEX NAME)

L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 862851-90-9 ZCAPLUS
CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-3-nitro- (CA INDEX NAME)

PAGE 1-A



L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

IT **862851-88-5P**, N-[4-[5-[(1,4-Diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]-4-nitrobenzamide **862851-90-9P**, N-[4-[5-[(1,4-Diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]-3-nitrobenzamide **862852-35-5P**, N-[4-[5-[(1,4-Diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]-4-nitrobenzamide hydrochloride **862852-37-7P**, N-[4-[5-[(1,4-Diazabicyclo[3.2.2]non-4-yl)carbonyl]furan-2-yl]phenyl]-3-nitrobenzamide hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of diazabicyclic aryl derivs. as nicotinic acetylcholine receptor ligands)

RN 862851-88-5 ZCAPLUS
CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-4-nitro- (CA INDEX NAME)

L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-A

RN 862852-35-5 ZCAPLUS
CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-4-nitro-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● HCl

RN 862852-37-7 ZCAPLUS
CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-3-nitro-, hydrochloride (1:1) (CA INDEX NAME)

L17 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

● HCl

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Et formate gave II in 53% yield. II showed inhibition of 3H-α-Bungarotoxine binding with IC50 value of 0.017μM. Thus, I and their pharmaceutical compns. are useful as cholinergic ligands at the nicotinic acetylcholine receptors for the treatment of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chem. substances (no data).

IT **753499-87-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diazabicyclic aryl derivs. as cholinergic ligands at the nicotinic acetylcholine receptors)

RN 753499-87-5 ZCAPLUS
CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:740327 ZCAPLUS
DN 141:260783
TI Preparation of diazabicyclic aryl derivatives as cholinergic ligands at the nicotinic acetylcholine receptors
IN Peters, Dan; Olsen, Gunnar M.; Nielsen, Elsebet Ostergaard; Jorgensen, Tino Dyhring; Ahring, Philip K.
PA Neurosearch A/S, Den.
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004076453	A1	20040910	2004WO-EP0050079	20040204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004215658	A1	20040910	2004AU-000215658	20040204
CA-----2518675	A1	20040910	2004CA-002518675	20040204
EP-----1599476	A1	20051130	2004EP-000707948	20040204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR--2004007216	A	20060124	2004BR-000007216	20040204
CN-----1738820	A	20060222	2004CN-080002423	20040204
CN-----1317280	C	20070523		
JP--2006519208	T	20060824	2006JP-000502001	20040204
NZ------540998	A	20080630	2004NZ-000540998	20040204
RU-----2338746	C2	20081120	2005RU-000118997	20040204
US-20060148789	A1	20060706	2005US-000547157	20050826
IN---200502058	A	20070831	2005IN-000002058	20050826
HK-----1084110	A1	20070928	2006HK-000104352	20060411
PRAI 2003DK-000000310	A	20030227		
2003US-00449871P	P	20030227		
2003DK-000000940	A	20030624		
2003US-00482022P	P	20030625		
2004WO-EP0050079	W	20040204		

OS MARPAT 141:260783
GI



I



II

AB Title compds. represented by the formula I [wherein X, Y = independently CR2, CR3, N; R1 = H, (cyclo)alkyl, halo, etc.; R2, R3 = independently H, (cycloalkyl)alkyl, nitro, aryl, etc.; n = 1-3; and their enantiomers, any mixture of enantiomers, a prodrug, or pharmaceutically acceptable salts thereof] were prepared as cholinergic ligands at the nicotinic acetylcholine receptors. For example, reaction of (1,4-diazabicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)furan-2-ylmethanone and

=> d bib abs hitstr l18 tot

L18 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:740327 ZCAPLUS
DN 141:260783
TI Preparation of diazabicyclic aryl derivatives as cholinergic ligands at the nicotinic acetylcholine receptors
IN Peters, Dan; Olsen, Gunnar M.; Nielsen, Elsebet Ostergaard; Jorgensen, Tino Dyhring; Anring, Philip K.
PA Neurosearch A/S, Den.
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004076453	A1	20040910	2004WO-EP0050079	20040204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2004215658	A1	20040910	2004AU-000215658	20040204
	CA-----2518675	A1	20040910	2004CA-002518675	20040204
	EP-----1599476	A1	20051130	2004EP-000707948	20040204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR--2004007216	A	20060124	2004BR-000007216	20040204
	CN-----1738820	A	20060222	2004CN-080002423	20040204
	CN-----1317280	C	20070523		
	JP--2006519208	T	20060824	2006JP-000502001	20040204
	NZ------540998	A	20080630	2004NZ-000540998	20040204
	RU-----2338746	C2	20081120	2005RU-000118997	20040204
	US-20060148789	A1	20060706	2005US-000547157	20050826
	IN---200502058	A	20070831	2005IN-000002058	20050826
	HK-----1084110	A1	20070928	2006HK-000104352	20060411
PRAI	2003DK-000000310	A	20030227		
	2003US-00449871P	P	20030227		
	2003DK-000000940	A	20030624		
	2003US-00482022P	P	20030625		
	2004WO-EP0050079	W	20040204		

OS MARPAT 141:260783
GI



I



II

AB Title compds. represented by the formula I [wherein X, Y = independently CR2, CR3, N; R1 = H, (cyclo)alkyl, halo, etc.; R2, R3 = independently H, (cycloalkyl)alkyl, nitro, aryl, etc.; n = 1-3; and their enantiomers, any mixture of enantiomers, a prodrug, or pharmaceutically acceptable salts thereof] were prepared as cholinergic ligands at the nicotinic acetylcholine

L18 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 753499-92-2 ZCAPLUS
CN Cyclopropanecarboxamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 753499-91-1
CMF C22 H25 N3 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L18 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
receptors. For example, reaction of (1,4-diazabicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)furan-2-ylmethanone and Et formate gave II in 53% yield. II showed inhibition of 3H-α-Bungarotoxine binding with IC50 value of 0.017μM. Thus, I and their pharmaceutical comps. are useful as cholinergic ligands at the nicotinic acetylcholine receptors for the treatment of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chem. substances (no data).
IT **753499-88-6P** **753499-91-1P** **753499-92-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diazabicyclic aryl derivs. as cholinergic ligands at the nicotinic acetylcholine receptors)
RN 753499-88-6 ZCAPLUS
CN Benzamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 753499-87-5
CMF C25 H25 N3 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 753499-91-1 ZCAPLUS
CN Cyclopropanecarboxamide, N-[4-[5-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-2-furanyl]phenyl]- (CA INDEX NAME)

L18 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 14:29:56 ON 17 AUG 2009)

     FILE 'ZCAPLUS' ENTERED AT 14:30:10 ON 17 AUG 2009
L1            1 US20080227772/PN

     FILE 'REGISTRY' ENTERED AT 14:30:24 ON 17 AUG 2009

     FILE 'ZCAPLUS' ENTERED AT 14:30:24 ON 17 AUG 2009
L2              TRA L1 1- RN :       74 TERMS

     FILE 'REGISTRY' ENTERED AT 14:30:24 ON 17 AUG 2009
L3           74 SEA L2
L4           46 L3 AND NC5-NC2NC3/ES AND OC4/ES
L5              STR
L6          225 (NC5-NC2NC3 AND OC4)/ES
L7            2 L5 SAM SUB=L6
L8           14 L5 FULL SUB=L6
                SAV TEM J749C1G2/A L8
L9           11 L8 AND L3
L10           3 L8 NOT L9
L11        2599 C25H25N3O3
L12           4 L11 AND L6
L13           3 L12 AND L3
L14           1 L12 NOT L13
L15          11 L9,L13
L16           3 L10,L14

     FILE 'ZCAPLUS' ENTERED AT 14:47:41 ON 17 AUG 2009
L17           2 L15
L18           1 L16

=>
```